FinnCap Reaffirms “Corporate” Rating for Cello Health (LON:CLL)

Share on StockTwits

FinnCap reissued their corporate rating on shares of Cello Health (LON:CLL) in a research report report published on Tuesday morning, ThisIsMoney.Co.Uk reports.

Shares of LON CLL opened at GBX 127 ($1.66) on Tuesday. The company has a current ratio of 1.28, a quick ratio of 1.23 and a debt-to-equity ratio of 4.70. The stock has a market capitalization of $134.73 million and a PE ratio of 20.82. The stock’s fifty day simple moving average is GBX 125.72 and its two-hundred day simple moving average is GBX 127.17. Cello Health has a 12-month low of GBX 95 ($1.24) and a 12-month high of GBX 140.07 ($1.83).

The business also recently announced a dividend, which will be paid on Friday, November 1st. Shareholders of record on Thursday, October 3rd will be given a dividend of GBX 1.15 ($0.02) per share. The ex-dividend date of this dividend is Thursday, October 3rd. This represents a yield of 0.91%. Cello Health’s dividend payout ratio (DPR) is presently 0.66%.

Cello Health Company Profile

Cello Health plc, together with its subsidiaries, provides marketing services in the United Kingdom, Rest of Europe, the United States, and internationally. It operates in two segments, Cello Health and Cello Signal. The Cello Health segment offers market research, consulting, and communications services principally to the pharmaceutical and healthcare clients.

Featured Article: How a Strangle Strategy is different from a Straddle Strategy

Receive News & Ratings for Cello Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Health and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

UBS Group Reaffirms “Neutral” Rating for AVEVA Group
UBS Group Reaffirms “Neutral” Rating for AVEVA Group
HC Wainwright Reiterates Buy Rating for Celldex Therapeutics
HC Wainwright Reiterates Buy Rating for Celldex Therapeutics
Helios Technologies  Expected to Post Earnings of $0.37 Per Share
Helios Technologies Expected to Post Earnings of $0.37 Per Share
Canaccord Genuity Trims Stobart Group  Target Price to GBX 190
Canaccord Genuity Trims Stobart Group Target Price to GBX 190
Dash  Trading Down 2.7% Over Last 7 Days
Dash Trading Down 2.7% Over Last 7 Days
NEM One Day Volume Hits $13.35 Million
NEM One Day Volume Hits $13.35 Million


 
© 2006-2019 Zolmax.